Sex and female empowerment (SAFE): A randomized trial comparing sexual health interventions for women in treatment for opioid use disorder.
Adult
Cognitive Behavioral Therapy
/ methods
Contraception
/ psychology
Contraception Behavior
/ psychology
Empowerment
Feasibility Studies
Female
Humans
Internet-Based Intervention
Linear Models
Long-Acting Reversible Contraception
/ psychology
Opioid-Related Disorders
/ psychology
Patient Acceptance of Health Care
/ psychology
Pilot Projects
Pregnancy
Reproductive Health Services
Sexual Health
Treatment Outcome
Young Adult
Birth control
Buprenorphine
Contraceptive practices
LARC
Methadone
Opioids
Sex
Women
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
18
10
2020
revised:
02
02
2021
accepted:
04
02
2021
pubmed:
7
3
2021
medline:
2
7
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
Unintended pregnancies are prevalent among women with opioid use disorder (OUD). The Sex and Female Empowerment (SAFE) project developed a social-cognitive, theory-driven intervention to increase acceptance of and adherence to contraceptive practices among women receiving medication for OUD (MOUD). This study evaluated the feasibility and acceptability of two SAFE interventions (Face-to-face and Computer-adapted) compared to usual care as well as their efficacy to improve contraception utilization. This pilot randomized trial enrolled 90 heterosexual, non-pregnant, reproductive-age women receiving MOUD. Participants were randomized into either a: SAFE Face-to-face intervention, SAFE Computer-adapted intervention, or usual care (UC) condition (n = 30 each) and followed for 6 months. Outcome measures included intervention completion, intervention satisfaction, attendance at a contraception consultation appointment, and long-acting reversible contraceptive (LARC) method receipt. A generalized linear model was used for inferential testing and to estimate least squares means (predicted probabilities for binary outcomes) and their standard errors. Compared to the UC condition, both the SAFE Face-to-face and the SAFE Computer-adapted intervention had higher intervention completion [Means (Standard Errors) = 0.97 (.03) and 0.97 (.03), respectively, vs. 0.53 (.09); ps<.001], higher intervention satisfaction [Ms (SEs) = 3.7 (.11) and 3.8 (.11), respectively, vs. 3.1 (.11); ps<0.001), higher contraception consultation visit attendance [Ms(SEs) = 0.80 (.07) and 0.73 (.08) vs. 0.33 (.09); p < .001], and greater LARC receipt [Ms(SEs) = 0.77 (.08) and 0.73 (.08) vs. 0.23 (.08); p < .001). SAFE appears feasible and efficacious for supporting women in contraception decision-making. Integrating SAFE into women's comprehensive OUD treatment services holds promise to increase contraceptive decision-making and initiation of a chosen method.
Sections du résumé
BACKGROUND
Unintended pregnancies are prevalent among women with opioid use disorder (OUD). The Sex and Female Empowerment (SAFE) project developed a social-cognitive, theory-driven intervention to increase acceptance of and adherence to contraceptive practices among women receiving medication for OUD (MOUD). This study evaluated the feasibility and acceptability of two SAFE interventions (Face-to-face and Computer-adapted) compared to usual care as well as their efficacy to improve contraception utilization.
METHODS
This pilot randomized trial enrolled 90 heterosexual, non-pregnant, reproductive-age women receiving MOUD. Participants were randomized into either a: SAFE Face-to-face intervention, SAFE Computer-adapted intervention, or usual care (UC) condition (n = 30 each) and followed for 6 months. Outcome measures included intervention completion, intervention satisfaction, attendance at a contraception consultation appointment, and long-acting reversible contraceptive (LARC) method receipt. A generalized linear model was used for inferential testing and to estimate least squares means (predicted probabilities for binary outcomes) and their standard errors.
RESULTS
Compared to the UC condition, both the SAFE Face-to-face and the SAFE Computer-adapted intervention had higher intervention completion [Means (Standard Errors) = 0.97 (.03) and 0.97 (.03), respectively, vs. 0.53 (.09); ps<.001], higher intervention satisfaction [Ms (SEs) = 3.7 (.11) and 3.8 (.11), respectively, vs. 3.1 (.11); ps<0.001), higher contraception consultation visit attendance [Ms(SEs) = 0.80 (.07) and 0.73 (.08) vs. 0.33 (.09); p < .001], and greater LARC receipt [Ms(SEs) = 0.77 (.08) and 0.73 (.08) vs. 0.23 (.08); p < .001).
CONCLUSIONS
SAFE appears feasible and efficacious for supporting women in contraception decision-making. Integrating SAFE into women's comprehensive OUD treatment services holds promise to increase contraceptive decision-making and initiation of a chosen method.
Identifiants
pubmed: 33676071
pii: S0376-8716(21)00129-0
doi: 10.1016/j.drugalcdep.2021.108634
pmc: PMC8048040
mid: NIHMS1679049
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108634Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002648
Pays : United States
Organisme : NIDA NIH HHS
ID : R34 DA033442
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Health Aff (Millwood). 2020 May;39(5):764-767
pubmed: 32364857
J Addict Med. 2020 Sep/Oct;14(5):e175-e182
pubmed: 32271200
Contraception. 2017 Nov;96(5):365-369
pubmed: 28778423
J Subst Abuse Treat. 2012 Oct;43(3):366-76
pubmed: 22444420
Violence Vict. 2009;24(6):744-56
pubmed: 20055212
Soc Sci Med. 2003 Nov;57(9):1593-608
pubmed: 12948569
Health Educ Behav. 2004 Apr;31(2):143-64
pubmed: 15090118
Contraception. 2018 Jan;97(1):76-78
pubmed: 28887052
Drug Alcohol Depend. 2019 Dec 1;205:107652
pubmed: 31704383
Pediatrics. 2019 Aug;144(2):
pubmed: 31320466
Obstet Gynecol. 2020 Feb;135(2):361-369
pubmed: 31923070
Drug Alcohol Depend. 2018 Apr 1;185:207-213
pubmed: 29462768
J Subst Abuse Treat. 2011 Mar;40(2):199-202
pubmed: 21036512
JAMA. 2019 Nov 26;322(20):1996-2016
pubmed: 31769830
Subst Abuse. 2016 May 12;10(Suppl 1):27-33
pubmed: 27199563
J Addict Med. 2019 May/Jun;13(3):177-181
pubmed: 30394994
Am J Addict. 2018 Jul 11;:
pubmed: 29995313
Prev Med. 2015 Nov;80:23-31
pubmed: 25900803
Womens Health Issues. 2019 Mar - Apr;29(2):176-181
pubmed: 30446331
Contraception. 2009 Mar;79(3):194-8
pubmed: 19185672
Subst Use Misuse. 2020;55(1):95-107
pubmed: 31455128
J Addict Med. 2019 Nov/Dec;13(6):420-421
pubmed: 31689258
J Addict Med. 2019 Nov/Dec;13(6):422-429
pubmed: 31689259
Contraception. 2020 May;101(5):333-337
pubmed: 32014521
Prev Med. 2016 Nov;92:62-67
pubmed: 27346756
Prev Med. 2019 Nov;128:105794
pubmed: 31398412
J Subst Abuse Treat. 2019 Mar;98:73-77
pubmed: 30665607
Aust N Z J Obstet Gynaecol. 2012 Apr;52(2):146-50
pubmed: 22335489